Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

A century ago, the strange behavior of atoms and elementary particles led physicists to formulate a new theory of nature. That theory, quantum mechanics, found immediate success, proving its worth ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

We are in for a chaotic and fun-filled weekend on the MLB front. Ready to see what's at stake ahead as teams play their final regular season series? Here's what on tap on Friday: Toronto can clinch ...

If you’re searching for the perfect baby girl name, those starting with the letter R are among the most charming and versatile. From classic choices like Rachel and Rebecca to trending favorites such ...

Palantir's stock is up nearly 10 % month-to-date and has gone even higher year-to-date, as bullish sentiment surges ahead of its second quarter earnings. Tempus AI shares, currently at about $64, have ...